This article highlights the ongoing debate on the ethics and accessibility of cell and gene therapies, particularly for treating rare diseases. While these therapies can offer lifesaving benefits, many patients lack access due to factors like cost and distribution. The industry grapples with ethical dilemmas such as how to balance innovation and accessibility, and how to democratize access to critical treatments.
CISA Releases Security Advisory on 13 Industrial Control System Threats
The Cybersecurity and Infrastructure Security Agency (CISA) issued thirteen advisories to address vulnerabilities in industrial control systems (ICS), mainly in various Siemens systems and products
